On July 2, Kelun-Biotech rose 8.39% in regular trading, trading at HK$466.2/share, with turnover of HK$281 million.

The rally was driven by continued market enthusiasm following the company's landmark Phase III OptiTROP-Lung05 clinical data presented at the ASCO annual meeting, combined with broad-based biotech sector strength. The study demonstrated that sac-TMT combined with pembrolizumab significantly improved progression-free survival versus pembrolizumab monotherapy in first-line PD-L1 positive advanced NSCLC patients, with a PFS hazard ratio of 0.35 and 12-month PFS rate of 62.4% versus 29.0%. Multiple institutions have issued bullish calls, with Nomura raising its target price to HK$544.42 maintaining a Buy rating, Industrial Securities initiating with an Overweight rating, and CITIC Construction Investment and China Post Securities both maintaining Buy ratings.

Within the Biotechnology sector, peers also rallied notably, with Transthera-B up 9.26%, 3SBio up 8.23%, Akeso up 6.64%, Innovent Bio up 5.46%, and BeiGene up 2.0%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)